SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is trending as investors consider its role as a defensive, high-dividend value play amidst a broader market rotation from high-flying tech stocks. The community is actively debating the significance of its upcoming planned separation into two companies and new CEO leadership, often dismissing recent analyst downgrades as deliberate market manipulation to facilitate accumulation at lower prices. Many anticipate substantial upside and a compelling dividend yield, contrasting with ongoing concerns about competitive pressures and past performance.

JERRY (JYAI) is a Matt Furie's artistic style; it features an AI-powered content creation hub that produces community-driven video series and art.  Jerry the Turtle, created by Matt Furie, is a character inspired by Furie’s artistic style. JERRY is also an AI-driven meme coin with an ambitious vision. The goal is to establish an AI-powered production house dedicated to creating a video series or episodes featuring characters from Matt Furie’s universe alongside those from Jerry’s world.  This unique blend of characters aims to produce the ultimate crypto-based series. Additionally, we are developing an app that will offer an exclusive, ad-free video series featuring characters from both Matt Furie’s creations and the Jerry Universe. Users will be able to download and share videos directly through the platform.  But that’s not all! A special Jerry Art Panel will showcase original Jerry characters, artwork, and fan creations—free to explore, download, and share with the community.

Jerry The Turtle By Matt Furie

Jerry The Turtle ($JYAI) is gaining traction following recent exchange listings, including Bitget, and a developer update addressing selling pressure, fueling community confidence. Enthusiasts are actively discussing its potential to become the next major memecoin, drawing comparisons to $PEPE, and anticipating further Tier 1 exchange listings as part of its ambitious growth strategy.

Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgical, diagnostic tests, infection-control products, and vitamins. The Technology and Value-Added Services segment offers financial on a non-recourse basis, network, and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.

Henry Schein Inc.

Henry Schein is trending due to significant strategic developments, including securing exclusive US distribution rights for Curodont and rolling out new AI-powered dental workflows, which are expected to boost its Dental business. These positive catalysts are reinforced by a major strategic investment from KKR and a recent share repurchase program. The community is actively discussing how these moves, combined with recent analyst upgrades, position Henry Schein for a potential rebound within the broader MedicalTech sector.

Akamai Technologies, Inc. engages in the provision of cloud services for delivering, optimizing, and securing content and business applications over the Internet. Its products include security, web performance, media delivery, and network operator. The company was founded by Frank T. Leighton, Jonathan Seelig, Randall S. Kaplan, and Daniel M. Lewin on August 20, 1998 and is headquartered in Cambridge, MA.

Akamai Technologies Inc

Akamai Technologies is trending due to a wave of recent analyst upgrades from firms like Morgan Stanley and Guggenheim, highlighting accelerated growth in its security and cloud computing segments. The community is actively discussing Akamai's strategic pivot into AI infrastructure and edge computing, particularly its NVIDIA partnership, positioning it as a key, and potentially undervalued, player in handling evolving AI workloads.

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Sutro Biopharma Inc

Sutro Biopharma is a hot topic as it navigates the aftermath of a recent reverse stock split and works to maintain Nasdaq compliance. Community sentiment is sharply divided: many bulls highlight a strengthened cash runway into 2027, insider buying, and anticipated milestone payments from collaborations as catalysts for a potential rebound. However, bears express significant frustration over management's strategic "deprioritization" of its Luvelta asset, despite positive clinical data, and question the path forward for its next-generation Antibody-Drug Conjugate pipeline amid a challenging biotech landscape.

Lynas Rare Earths Ltd. engages in the production of rare earth minerals. It focuses on the exploration, development, mining, and processing of rare earth deposits. The company was founded by Nicholas Anthony Curtis on May 23, 1983 and is headquartered in Perth, Australia.

Lynas Rare Earths Limited

Lynas Rare Earths is trending as strategic partnerships and substantial US government backing highlight ongoing efforts to establish a non-Chinese rare earth supply chain. Community discussion centers on Lynas's pivotal role in global independence for critical minerals, driven by increasing demand from sectors like AI and electric vehicles, with an upcoming quarterly report anticipated to provide further insight.

Ethereum Classic

Ethereum Classic (ETC) is trending with significant community discussion, as many anticipate a major surge for the 'classic' Proof-of-Work altcoin amid broader market optimism driven by upcoming regulatory clarity and increased liquidity. Despite some frustration over its relative performance, enthusiasts are actively accumulating, viewing current price levels as a prime buying opportunity before an expected breakout.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific is trending due to its recent definitive agreement to acquire Penumbra for $14.5 billion, a strategic move aiming to significantly expand its vascular medicine business. While some investors are concerned about potential integration costs, the broader community largely views BSX as an oversold, high-quality healthcare investment. This sentiment is reinforced by its strong product pipeline, including the FARAPULSE PFA system, and a history of positive financial performance, leading many to anticipate a strong recovery.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quant (QNT) is actively discussed as a crucial player in institutional blockchain adoption, driven by its Overledger platform powering initiatives like the UK's tokenized deposit pilot with major banks. The community anticipates significant long-term growth from QNT's limited supply and developing Quant Fusion update for multi-chain interoperability, even amidst some short-term price frustrations.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

Dash is generating significant buzz following its integration with ACH and rumored major collaborations, driving it into the top traded assets on Coinbase. The community is actively discussing its potential for a substantial rally, positioning this 'OG privacy coin' to mirror the recent strong performances seen in Zcash and Monero.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON (etonogestrel implant) 68 mg Radiopaque

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the US Food and Drug Administration (FDA...

Organon (OGN) Exceeds Market Returns: Some Facts to Consider

In the closing of the recent trading day, Organon (OGN) stood at $8.7, denoting a +1.05% move from the preceding trading day.

Nordea Investment Management AB Has $31.71 Million Position in Organon & Co. $OGN

Nordea Investment Management AB lessened its holdings in shares of Organon & Co. (NYSE:OGN - Free Report) by 37.1% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned...

Organon (OGN) Increases Despite Market Slip: Here's What You Need to Know

Organon (OGN) reached $8.61 at the closing of the latest trading day, reflecting a +2.14% change compared to its last close.

Organon & Co. Sees Unusually Large Options Volume (NYSE:OGN)

Organon & Co. (NYSE:OGN - Get Free Report) saw unusually large options trading activity on Tuesday. Investors acquired 17,794 call options on the company. This is an increase of 550% compared to the...

Organon (OGN) Surpasses Market Returns: Some Facts Worth Knowing

Organon (OGN) concluded the recent trading session at $7.44, signifying a +2.76% move from its prior day's close.

Organon & Co. (NYSE:OGN) Upgraded at Wall Street Zen

Wall Street Zen raised Organon & Co. from a "hold" rating to a "buy" rating in a report on Saturday...

Gilman Hill Asset Management LLC Reduces Position in Organon & Co. $OGN

Gilman Hill Asset Management LLC lessened its holdings in shares of Organon & Co. (NYSE:OGN - Free Report) by 87.3% in the third quarter, according to its most recent disclosure with the Securities...

Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock

Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Organon (OGN) Beats Stock Market Upswing: What Investors Need to Know

In the latest trading session, Organon (OGN) closed at $6.98, marking a +2.2% move from the previous day.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Organon & Co.

Organon (OGN) is currently a focal point for investors, following significant regulatory wins including the FDA approval of VTAMA for atopic dermatitis and Hadlima's designation as an interchangeable biosimilar to Humira, securing a key formulary spot. While a recent internal audit and a dividend adjustment for debt reduction caused immediate market reaction, the community is actively discussing the company's deeply undervalued metrics and long-term potential in women's health and biosimilars, often viewing current prices as a prime accumulation opportunity.

OGN
Organon & Co.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OGN News

OGNOrganon & Co.